| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1853.2 | 8.4 | 27.2 |
| Other income | 1.8 | 0.0 | 0.0 |
| Total income | 1855.0 | 8.4 | 27.2 |
| Profit before exceptional items & tax | 1761.0 | -68.0 | -60.7 |
| Exceptional items | 0.0 | -12.4 | 0.0 |
| Profit before tax | 1761.0 | -80.3 | -60.7 |
| Net profit | 1761.3 | -80.4 | -59.8 |
| Operating margin | 94.9% | -956.0% | -223.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +6713.20% |
|---|
Source
Read the filing ↗
NSE results filing, NSE: SPARC. Figures extracted from the filing.
Sun Pharma Advanced Research Company Ltd: key numbers
- Share price
- ₹209.05
- Market cap
- ₹6,784 Cr
- Revenue (annual)
- ₹1,879 Cr
- Net profit (annual)
- ₹1,553 Cr
- P/E (TTM)
- 4.3×Sector 50.4×
- Promoter holding
- 65.67%+0.00% QoQ
- FII holding
- 3.90%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharma Advanced Research Company Ltd
All →
13:29 IST
BSE
Financial Results
Sun Pharma Advanced Research Company Q1 FY27 Results: Net Loss of ₹20.8 Cr, Loss Narrows
Sun Pharma Advanced Research Company Ltd reported revenue from operations of ₹39.9 Cr (+315.6% YoY) and a net loss of ₹20.8 Cr for Q1 FY27.
- Key figure
- Net loss ₹20.8 Cr